Cmet Dependent Malignancies clinical trials

Explore recruiting cmet dependent malignancies clinical trials.

Also recruiting in Europe

Cmet Dependent Malignancies trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

An open-label, multi-center, global, rollover study for patients who have previously been treated with capmatinib (INC280) as monotherapy or in combination in a Novartis Sponsored trial

Belgium, Germany, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Cmet Dependent Malignancies trials by city

Cmet Dependent Malignancies in Toronto Cmet Dependent Malignancies in Vancouver Cmet Dependent Malignancies in Montreal Cmet Dependent Malignancies in Calgary Cmet Dependent Malignancies in Edmonton Cmet Dependent Malignancies in Ottawa Cmet Dependent Malignancies in Winnipeg Cmet Dependent Malignancies in Quebec City Cmet Dependent Malignancies in Hamilton Cmet Dependent Malignancies in Kitchener Cmet Dependent Malignancies in London Cmet Dependent Malignancies in Halifax Cmet Dependent Malignancies in New York Cmet Dependent Malignancies in Los Angeles Cmet Dependent Malignancies in Chicago Cmet Dependent Malignancies in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease